news New combination treatment enables targeting of non-responsive lung tumours The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises… 26 September 2024 | By Drug Target Review The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.